Advertisement
ADMA vs RGNX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and RGNX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADMA’s FA Score shows that 2 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).
- ADMA’s FA Score: 2 green, 3 red.
- RGNX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADMA’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).
- ADMA’s TA Score: 4 bullish, 5 bearish.
- RGNX’s TA Score: 4 bullish, 3 bearish.
Price Growth
ADMA (@Biotechnology) experienced а -2.87% price change this week, while RGNX (@Biotechnology) price change was -1.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.
Reported Earning Dates
ADMA is expected to report earnings on Mar 19, 2026.
RGNX is expected to report earnings on Mar 03, 2026.
Industries' Descriptions
@Biotechnology (+0.31% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ADMA | RGNX | ADMA / RGNX | |
| Capitalization | 4.35B | 757M | 575% |
| EBITDA | 172M | -120M | -143% |
| Gain YTD | 0.219 | 3.819 | 6% |
| P/E Ratio | 21.26 | N/A | - |
| Revenue | 489M | 161M | 304% |
| Total Cash | 61.4M | 274M | 22% |
| Total Debt | 83.1M | 76.5M | 109% |
ADMA | RGNX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 33 | 100 | |
SMR RATING 1..100 | 17 | 98 | |
PRICE GROWTH RATING 1..100 | 57 | 38 | |
P/E GROWTH RATING 1..100 | 98 | 22 | |
SEASONALITY SCORE 1..100 | 36 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADMA's Valuation (74) in the Biotechnology industry is in the same range as RGNX (74). This means that ADMA’s stock grew similarly to RGNX’s over the last 12 months.
ADMA's Profit vs Risk Rating (33) in the Biotechnology industry is significantly better than the same rating for RGNX (100). This means that ADMA’s stock grew significantly faster than RGNX’s over the last 12 months.
ADMA's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for RGNX (98). This means that ADMA’s stock grew significantly faster than RGNX’s over the last 12 months.
RGNX's Price Growth Rating (38) in the Biotechnology industry is in the same range as ADMA (57). This means that RGNX’s stock grew similarly to ADMA’s over the last 12 months.
RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ADMA (98). This means that RGNX’s stock grew significantly faster than ADMA’s over the last 12 months.
| ADMA | RGNX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 76% | N/A |
| Stochastic ODDS (%) | 3 days ago 85% | 1 day ago 89% |
| Momentum ODDS (%) | 3 days ago 79% | 1 day ago 82% |
| MACD ODDS (%) | 3 days ago 76% | 1 day ago 85% |
| TrendWeek ODDS (%) | 3 days ago 80% | 1 day ago 84% |
| TrendMonth ODDS (%) | 3 days ago 79% | 1 day ago 78% |
| Advances ODDS (%) | 9 days ago 86% | 9 days ago 77% |
| Declines ODDS (%) | 3 days ago 76% | 1 day ago 84% |
| BollingerBands ODDS (%) | 3 days ago 74% | 1 day ago 90% |
| Aroon ODDS (%) | 3 days ago 79% | 1 day ago 69% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SSLCX | 54.59 | 0.29 | +0.53% |
| DWS Small Cap Core S | |||
| RVVHX | 10.20 | 0.02 | +0.20% |
| Royce Small-Cap Value Investment | |||
| FTZCX | 65.21 | -0.10 | -0.15% |
| FullerThaler Behvrll Uncnstd Eq C | |||
| BGETX | 14.45 | -0.09 | -0.59% |
| Baillie Gifford International Growth 2 | |||
| ANFCX | 58.60 | -0.61 | -1.03% |
| American Funds New Economy C | |||
ADMA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VIR. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
|---|---|---|---|---|
| ADMA | 100% | +3.28% | ||
| VIR - ADMA | 42% Loosely correlated | +8.08% | ||
| IMTX - ADMA | 40% Loosely correlated | +4.80% | ||
| CPRX - ADMA | 39% Loosely correlated | +3.67% | ||
| IDYA - ADMA | 39% Loosely correlated | +5.53% | ||
| RGNX - ADMA | 39% Loosely correlated | -0.66% | ||
More | ||||
RGNX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To RGNX | 1D Price Change % | ||
|---|---|---|---|---|
| RGNX | 100% | -0.66% | ||
| SYRE - RGNX | 56% Loosely correlated | +5.17% | ||
| BEAM - RGNX | 55% Loosely correlated | +2.49% | ||
| VYGR - RGNX | 55% Loosely correlated | +2.74% | ||
| XNCR - RGNX | 54% Loosely correlated | +3.66% | ||
| DNLI - RGNX | 52% Loosely correlated | +0.88% | ||
More | ||||